Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials

Sho Tashiro,Takayuki Mihara, Moe Sasaki,Chiaki Shimamura,Rina Shimamura, Shiho Suzuki, Maiko Yoshikawa,Tatsuki Hasegawa,Yuki Enoki,Kazuaki Taguchi,Kazuaki Matsumoto,Hiroki Ohge,Hiromichi Suzuki,Atsushi Nakamura,Nobuaki Mori,Yoshitomo Morinaga,Yuka Yamagishi,Sadako Yoshizawa,Katsunori Yanagihara,Hiroshige Mikamo,Hiroyuki Kunishima

Journal of Infection and Chemotherapy（2022）

引用 11|浏览5

暂无评分

摘要

FDX achieves significantly higher global cure rates and lower recurrence rates and is comparable to VCM in clinical cure rates and adverse event rates in patients with CDI. Collectively, FDX is superior to VCM as a therapeutic agent for CDI.

查看译文

关键词

Clostridioides difficile infection,Fidaxomicin,Vancomycin,Global cure,Recurrence,Meta-analysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要